Neuronetics joins a B. Riley Securities panel on emerging therapies and device-based mental health treatment at the 2023 Neuroscience and Mental Health Conference

Neuronetics is participating in a panel discussion at the B. Riley Securities 2023 Neuroscience and Mental Health Conference, positioning device-based treatment within a broader conversation about emerging mental health therapies. The company is known for NeuroStar Advanced Therapy, a transcranial magnetic stimulation system used for major depressive disorder and other psychiatric indications. The event connects investors, executives, and mental health innovators around commercial strategy, clinical adoption, and the evolving treatment landscape. Neuronetics' presence signals mainstream market interest in non-drug neuropsychiatric interventions alongside newer brain health and mental health technologies. The discussion matters because capital markets increasingly treat mental health treatment as a growth sector that includes both pharmaceuticals and medical devices. NeuroStar's inclusion highlights how neuromodulation is being framed as part of the next wave of scalable psychiatric care.